What is really happening to your hair, why it is happening now, and what the latest clinical evidence says about addressing it

The Symptom That Hits at Identity

Of all the visible changes of perimenopause and menopause, hair loss is among the most emotionally significant. Skin can be covered; hair loss is harder to conceal and harder still to accept. Women who have always defined part of their identity through their hair – its thickness, its texture, the way it frames their face – find its thinning during this transition profoundly disorienting.

Yet hair loss during perimenopause and menopause receives remarkably little clinical attention relative to its prevalence and its emotional impact. Women are often told their hair loss is “normal for your age,” given minimal guidance, and sent away without a treatment plan or even a diagnosis.

This article changes that. It explains the biology, presents the clinical data, and maps the full evidence-based treatment landscape – from the gold-standard pharmacological options now supported by international expert consensus to the nutritional and lifestyle strategies that support them.

Part 1: The Biology – Why Hormonal Change Disrupts Hair

The Hair Cycle: A Primer

Every hair follicle on the scalp operates on an independent cycle of three phases: anagen (active growth, lasting 2–7 years), catagen (transition, lasting 2–3 weeks), and telogen (resting/shedding, lasting 3–4 months). The density and apparent thickness of hair at any given time reflects the proportion of follicles in anagen versus telogen – approximately 85–90% of healthy scalp follicles are in anagen at any moment.

Both estrogen and progesterone support this balance. Estrogen prolongs the anagen phase and suppresses the enzymes that convert testosterone to the more potent androgen dihydrotestosterone (DHT). Progesterone inhibits 5-alpha-reductase – the enzyme that drives this conversion. When both hormones fall in perimenopause and menopause, the anagen phase shortens, more follicles enter telogen simultaneously, and the relative influence of androgens – including DHT – increases. The result is progressive follicular miniaturization: follicles shrink over successive cycles, producing progressively thinner, shorter hairs, until some cease production entirely.

The Latest Research: Menopause and Hair Loss Explored in Depth

A comprehensive systematic literature review published in Maturitas in July 2025 by researchers at the University of Toronto – one of the most thorough to date on this specific topic – confirmed the mechanistic picture and added important nuance: multiple factors contribute to hair loss in postmenopausal women, including hormonal changes, genetics, and lifestyle habits. Female pattern hair loss is more common after menopause, strongly suggesting that hormones play a central role in its development and progression.

The same 2025 review highlighted a critical distinction that clinicians often miss: menopausal hair loss is not a single entity. It encompasses at least three distinct clinical presentations that require different management approaches.

Three Types of Hair Loss During Menopause – Why the Distinction Matters

1. Female Pattern Hair Loss (FPHL) / Androgenetic Alopecia

Androgenetic alopecia is the most common hair loss type in women. The pathophysiology involves shortened anagen phases, lengthened telogen phases, and hair follicle miniaturisation. Androgens, particularly dihydrotestosterone (DHT), play a crucial role in male androgenetic alopecia pathogenesis, but their exact role in female pattern hair loss is less clear.

FPHL in women produces a characteristically different pattern from male baldness. Rather than a receding hairline or bald crown, women experience diffuse thinning across the top and front of the scalp – a widening parting line, reduced volume, and progressively visible scalp. The Ludwig Scale (I–III) and BASP classification are the standard clinical assessment tools. Prevalence increases markedly with age: approximately 12% before menopause, rising to over 50% in women over 70.

2. Telogen Effluvium (TE)

Telogen effluvium is a diffuse, typically temporary form of hair loss caused by a systemic stressor that pushes a large proportion of follicles simultaneously into the telogen phase. The shedding occurs 2–4 months after the trigger – which means women often cannot connect the hair loss to its cause.

During perimenopause, the hormonal fluctuations themselves constitute a sustained systemic stressor. Sleep deprivation, nutritional depletion, thyroid dysfunction (which co-occurs commonly with menopause), and elevated cortisol are all triggers that overlap with this life stage. TE typically presents as diffuse, generalized shedding – handfuls in the shower, heavy accumulation on pillowcases – rather than patterned thinning. Crucially, TE is largely reversible when the trigger is identified and addressed.

3. Frontal Fibrosing Alopecia (FFA)

FFA is a scarring (cicatricial) alopecia – a progressive inflammatory condition that destroys follicles permanently, producing a characteristic band of hair loss along the frontal hairline and temples. Its incidence has increased dramatically over the past two decades, and it shows a striking association with postmenopausal status. The cause is not fully understood, but hormonal, genetic, and environmental (including certain sunscreen chemicals and personal care products) factors are implicated. Because FFA produces permanent follicle destruction, early diagnosis and treatment – with a dermatologist – is essential. Any woman noticing recession of the hairline, loss of eyebrows, or small bumps around hair follicles at the temple should seek specialist assessment promptly.

The Genetic Dimension

A 2026 review in PMC confirmed that hair loss susceptibility is polygenic – influenced by many genes rather than inherited simply. Recent genetic research has shown that hair loss is influenced by many genes that affect how hair follicles grow, survive, and respond to hormones. These genes act through several biological pathways, leading to progressive thinning of hair follicles over time. Genetic risk also differs between populations.

The maternal family history is particularly relevant: having a mother with female pattern hair loss significantly elevates risk. However – and this is an important clinical message – genetic predisposition is not destiny. The presence of genetic risk means early intervention is more, not less, important: treatment initiated before miniaturisation is advanced produces significantly better outcomes.

The Psychological Dimension

Female pattern hair loss is a common yet understudied condition with significant psychosocial impacts. Research documents elevated rates of anxiety, depression, social withdrawal, and reduced quality of life in women with significant hair loss. The relationship between FPHL and depression is bidirectional – hair loss causes depression, and depression itself (and the medications that treat it) can worsen hair loss. This self-reinforcing cycle deserves clinical recognition and active management.

Part 2: Nutritional and Lifestyle Factors – What Makes It Better and Worse

The Nutrients Most Critical for Hair Follicle Health

Iron: Iron deficiency is the most common – and most commonly missed – nutritional driver of hair loss in perimenopausal women. The heavy periods characteristic of perimenopause substantially increase iron losses. Crucially, serum ferritin (the body’s iron storage protein) can be depleted well before full anemia develops – and hair follicles are exquisitely sensitive to ferritin levels. A serum ferritin below 30 ng/mL is associated with impaired hair growth, and most trichologists consider 70 ng/mL the optimal minimum for hair health. If you are shedding significantly and have not had a ferritin test, this is the first investigation to request.

Biotin (Vitamin B7): Biotin deficiency produces brittle, thinning hair. Supplementation at 2,500–3,000 mcg daily has demonstrated benefit for nail and hair quality in clinical trials. Important clinical caveat: high-dose biotin interferes with thyroid function tests and several cardiac biomarker assays – inform your clinician before testing.

Zinc: Required for DNA synthesis in rapidly dividing hair matrix cells. Deficiency produces characteristic shedding and, at higher levels of depletion, white spots on nails. Dietary sources include red meat, shellfish, seeds, and legumes. Supplementation at 8–11 mg daily where dietary intake is insufficient.

Vitamin D: Vitamin D receptors are present in hair follicles, where they regulate the hair cycle. Deficiency – prevalent in 40–70% of postmenopausal women in temperate climates – is associated with both FPHL and diffuse shedding. Test, correct to above 50 nmol/L, and maintain.

Protein: Hair is composed almost entirely of keratin – a protein. Insufficient dietary protein (below 1.0 g/kg body weight daily) directly impairs hair matrix cell activity. This is particularly relevant for women who have reduced appetite during perimenopause, are intermittent fasting aggressively, or have unintentionally reduced protein intake as part of weight management.

Omega-3 fatty acids: Reduce the scalp inflammation that contributes to follicular miniaturisation, and support the lipid-rich environment of the hair follicle. EPA and DHA at 1–2g daily from supplements or dietary sources (oily fish, walnuts, flaxseed).

Lifestyle Factors That Worsen Hair Loss

Chronic stress and elevated cortisol – one of the most significant and least addressed triggers. Cortisol disrupts the hair cycle directly by increasing the proportion of follicles in telogen. Mindfulness, exercise, and sleep optimization are not merely wellness suggestions – they are evidence-supported interventions for hair loss.

Crash dieting and rapid weight loss – produce telogen effluvium through caloric and nutritional deprivation. The hair loss from crash dieting typically appears 2–4 months after the weight-loss period, making the connection non-obvious.

Smoking – reduces blood flow to follicles, generates oxidative stress in follicular tissue, and independently increases androgenetic alopecia severity. Cessation is a direct hair health intervention.

Heat styling and mechanical stress – while not a cause of FPHL, they accelerate visible thinning by increasing breakage in already-fragile miniaturised hair. Reducing heat, using a silk pillowcase, and avoiding tight hairstyles that place traction on follicles are practical protective measures.

Thyroid dysfunction – hypothyroidism, in particular, produces diffuse hair loss that directly overlaps with the pattern of menopausal hair loss. Both conditions are more prevalent in midlife women and frequently co-occur. Any woman with significant hair loss during this transition should have TSH tested; an abnormal result points to a potentially fully reversible, separate cause.

Part 3: The Treatment Landscape – What the Latest Evidence Supports

The Most Significant Development of 2025: International Expert Consensus on Oral Minoxidil

The most clinically important development in the hair loss treatment landscape for 2025 was the publication of an international expert consensus statement on low-dose oral minoxidil in JAMA Dermatology – the first formally agreed best-practice guidelines for its use.

Low-dose oral minoxidil has gained recognition as an off-label treatment for hair loss disorders, including androgenetic alopecia, telogen effluvium, and alopecia areata. Originally developed to treat hypertension, its hair growth-promoting effects are attributed to multiple mechanisms: primarily through direct KATP channel activation in dermal papilla cells, with additional effects from Wnt/β-catenin signaling, enhanced cysteine incorporation, and modulation of inflammatory and androgenic pathways.

International Delphi consensus supports standardized dosing: 1.25 mg/day starting dose for women (range 0.625–5 mg/day), with lower doses recommended for adolescents and caution advised in renal/hepatic impairment. Contraindications include pericardial disease, uncontrolled hypertension, and pregnancy.

The practical significance of this consensus is substantial: it gives clinicians worldwide a formal framework for prescribing oral minoxidil off-label – and gives women access to a treatment that many find more convenient, more tolerable, and at least as effective as topical formulations.

The most frequent adverse effect of low-dose oral minoxidil is hypertrichosis (unwanted hair growth in other areas), occurring in approximately 15% of patients, with higher incidence in women and at higher doses. Fluid retention affects 1.3–10% of patients, typically within 1–3 months of treatment. These effects are dose-dependent and generally manageable through dose reduction.

Topical Minoxidil: Still the FDA-Approved Foundation

Topical minoxidil (2% and 5% formulations) remains the only FDA-approved treatment for female pattern hair loss and the evidence base is well-established. It works by prolonging the anagen phase, increasing follicular size, and stimulating new hair growth. Clinical trials consistently show 19–60% of women experiencing meaningful regrowth after 6–12 months of consistent use.

Practical realities: topical minoxidil requires daily application to a dry scalp, can cause scalp irritation and dryness in some women, and transfers to pillow and partner. Approximately 40% of women who have tried topical minoxidil discontinue it due to local side effects or adherence difficulty – which is precisely the clinical context in which oral minoxidil has emerged as the preferred alternative.

Anti-Androgen Therapies: Spironolactone and Beyond

Spironolactone – an oral anti-androgen medication originally developed as a diuretic – blocks androgen receptors in the hair follicle, reducing DHT’s miniaturising effect. Oral anti-androgens demonstrate some efficacy in women with female pattern hair loss, with considerations for side effects and contraindications.

At doses of 50–200 mg daily, spironolactone produces meaningful improvement in FPHL for many women and is frequently combined with topical minoxidil for enhanced effect. It is not appropriate for women who are pregnant or planning pregnancy.

Topical finasteride – a newer development that delivers the 5-alpha-reductase inhibiting effect of finasteride locally at the scalp, without the systemic absorption and associated side effects of oral finasteride – is gaining clinical traction and represents an important emerging option for women where spironolactone is contraindicated or poorly tolerated.

Hormone Therapy and Hair

For women experiencing hair loss as part of a broader menopausal symptom profile, MHT deserves specific consideration. Estrogen – when administered systemically – directly supports follicle health through the same mechanisms whose loss drives FPHL. A pilot study published in the International Journal of Women’s Dermatology found that estradiol replacement therapy produced measurable improvements in hair growth in postmenopausal Japanese women with FPHL. Oral micronised progesterone (as distinct from synthetic progestins) has specific additional benefit in this context, because it is metabolized to allopregnanolone and additionally inhibits 5-alpha-reductase activity – the same enzyme that drives DHT-mediated follicular miniaturisation.

Platelet-Rich Plasma (PRP) and Emerging Interventions

PRP – a treatment that concentrates the patient’s own growth factors from blood and injects them into the scalp – has accumulated a reasonable evidence base for FPHL, with multiple small trials demonstrating improvements in hair density and thickness. It is typically delivered in a series of three to four treatments over four to six months, followed by maintenance. It is not a replacement for pharmacological treatment but can complement it, particularly in women seeking to avoid or delay medication.

Low-level laser therapy (LLLT) – using photobiomodulation to stimulate follicular activity – has FDA clearance (not approval) for FPHL. The evidence is modest but positive for mild to moderate cases, and it is well-tolerated with no significant side effects. Home-use devices (laser caps and combs) make it accessible without clinic visits.

Microneedling of the scalp – creating micro-injuries that stimulate a wound-healing response in follicular tissue – has emerging but promising evidence, particularly as an adjunct to topical minoxidil application (micro-channels created by the needling enhance drug penetration).

Part 4: A Practical Action Plan

Step 1: Diagnose correctly. Not all hair loss is the same. A dermatologist with trichoscopy (digital scalp imaging) can distinguish FPHL from telogen effluvium, FFA, and other causes. Do not accept “it’s your age” without a diagnosis. Trichoscopy is a non-invasive, quick procedure that reveals follicular health invisible to the naked eye.

Step 2: Test comprehensively. Request: serum ferritin (target >70 ng/mL for hair health), TSH (thyroid function), full blood count, vitamin D (25-OHD), zinc, and B12. These investigations take 10 minutes and identify fully reversible causes of hair loss that are missed without them.

Step 3: Address nutritional foundations. Correct any identified deficiencies. Ensure protein intake of at least 1.0–1.2 g/kg body weight. Add omega-3 supplementation (1–2g EPA+DHA daily). Supplement vitamin D and zinc if deficient.

Step 4: Begin treatment early. The cardinal principle of hair loss management is that earlier intervention produces better outcomes. Follicular miniaturisation is progressive and partially irreversible; treatment preserves the follicles that remain, but cannot reliably restore those already lost. For most women, topical or oral minoxidil is the appropriate starting point – with the 2025 international consensus on oral minoxidil providing the framework for clinical prescribing.

Step 5: Consider hormonal support. Discuss MHT with a menopause-specialist clinician if hair loss coincides with other menopausal symptoms. Include oral micronised progesterone specifically in the conversation for its anti-androgenic hair benefits.

Step 6: Manage the psychological dimension. Hair loss during menopause has real, documented effects on mood, confidence, and quality of life. These deserve acknowledgement and support – whether through counselling, peer groups, or simply having a clinician who takes the impact seriously.

The Conclusion

Hair loss during perimenopause and menopause is one of the most prevalent, most distressing, and most treatable consequences of this hormonal transition. The science of its mechanisms is now well-established. The treatment landscape has genuinely advanced – particularly with the 2025 international expert consensus on oral minoxidil and the growing evidence base for combination approaches. And the nutritional and lifestyle foundations for hair health are practical, accessible, and evidence-supported.

What has not advanced sufficiently is clinical practice: too many women are still dismissed, undertreated, or told that thinning hair is inevitable. It is not. With the right diagnosis, the right investigations, and the right treatment – begun early – the majority of women can meaningfully protect their hair health through this transition.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Sources

1. Gupta AK, Economopoulos V, Mann A, Wang T, Mirmirani P. Menopause and hair loss in women: Exploring the hormonal transition. Maturitas. 2025;198:108378. doi:10.1016/j.maturitas.2025.108378
2. GoodRx / Bronstein L MD. Hair Loss Due to Menopause: What to Do About It. goodrx.com. Updated May 2026. (Citing: Rinaldi F et al., 2023; Owecka B et al., 2024; Grymowicz M et al., 2020; Zouboulis CC et al., 2022)
3. Forhers.com. Menopause Hair Loss. forhers.com. August 2025. (Citing: Kamp E et al., 2022; Owecka B et al., 2024; Hughes EC et al., 2024)
4. Burns LJ et al. Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current and emerging therapies. Journal of the American Academy of Dermatology. 2025. doi:10.1016/S0190-9622(25)00722-4
5. Fu Z et al. Research Trends and Hotspots in Female Pattern Hair Loss: A Bibliometric Study. Journal of Cosmetic Dermatology. 2025;24(8):e70369. doi:10.1111/jocd.70369
6. PMC12837269. The Genetic Landscape of Androgenetic Alopecia: Current Knowledge and Future Perspectives. PMC. 2026. (Published Jan 2026, received Dec 2025)
7. PMC12380480. Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment. PMC. 2025.
8. Akiska YM, Mirmirani P, Roseborough I et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatology. 2025;161(1):87–95. doi:10.1001/jamadermatol.2024.4593
9. Gupta AK, Talukder M. Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia. Expert Opinion on Pharmacotherapy. 2024;25(2):139–147. doi:10.1080/14656566.2024.2314087
10. Imhof R, Villalpando B, Torgerson R. Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD International. PMC10483043. 2023. doi:10.1016/j.jdin.2023.08.002
11. PMC11942662. Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review. PMC. Published through December 2024.
12. Lipner SR et al. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. American Journal of Clinical Dermatology. 2026;27(1):101–119. doi:10.1007/s40257-025-00990-4
13. JAAD. Summation and recommendations for the safe and effective use of topical and oral minoxidil. Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2025 (published April 2025)
14. PMC12188453. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. PMC. 2025.
15. Frontiers in Pharmacology. Topical, oral and sublingual minoxidil: overview of current evidence in androgenetic alopecia. frontiersin.org. 2025. doi:10.3389/fphar.2025.1718208
16. Rinaldi F et al. The Menopausal Transition: Is the Hair Follicle “Going through Menopause”? Biomedicines. 2023;11(11):3041. PMC10669803. doi:10.3390/biomedicines11113041
17. Kamp E et al. Menopause, skin and common dermatoses. Part 1: Hair disorders. PMC10092469. Clinical and Experimental Dermatology. 2022.
18. Owecka B et al. The hormonal background of hair loss in non-scarring alopecias. Biomedicines. 2024. PMC. doi:10.3390/biomedicines12020432
19. Chaikittisilpa S et al. Prevalence of Female Pattern Hair Loss in Postmenopausal Women: A Cross-Sectional Study. Menopause. 2022;29(4):415–420. doi:10.1097/gme.0000000000001927
20. Endo Y et al. Clinical and phototrichogrammatic evaluation of estradiol replacement therapy on hair growth in postmenopausal Japanese women with female pattern hair loss: A pilot study. International Journal of Women’s Dermatology. 2023.